Nls pharmaceutics announces receipt of nasdaq minimum bid price notification

Zurich, switzerland / accesswire / june 10, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp),(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a written notice (the "notice") from nasdaq stock market llc, indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in listing rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
NLSP Ratings Summary
NLSP Quant Ranking